Skip to main content
. 2023 Dec 21;16(1):47. doi: 10.3390/cancers16010047

Figure 4.

Figure 4

Kaplan–Meier estimates of a survival outcome in patients with non-small cell lung cancer (NSCLC) receiving proton pump inhibitors (PPIs) and those who did not receive PPIs within the 60-day window. (A) PPI user: overall survival (OS) in patients with NSCLC who received PPIs, stratified by CBM588 administration. (B) PPI non-user: OS of patients with NSCLC who did not receive PPIs, stratified by CBM588 administration.